{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:41:00Z","timestamp":1777920060872,"version":"3.51.4"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T00:00:00Z","timestamp":1688688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The sensitivity and specificity of clot lysis at 30 minutes after maximum clot strength (LY30), as measured by thromboelastography (TEG), for clinically significant hyperfibrinolysis have not been compared across the 2 US Food and Drug Administration\u2013approved instruments (the TEG 5000 and TEG 6s [Haemonetics]).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a retrospective, single-center analysis of these 2 instruments using the kaolin (CK) reagent.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Local verification studies showed that the TEG 5000 and TEG 6s CK LY30 upper limits of normal (ULNs) were distinct (5.0% and 3.2%, respectively). Retrospective analysis of patient data showed that abnormal LY30 was 6 times more prevalent with the TEG 6s than with the TEG 5000 instrument. LY30 was a significant predictor of mortality with both instruments (TEG 6s: receiver operating characteristic [ROC] area under the curve [AUC] = 0.836, P \u2264 .0001; TEG 5000: ROC AUC = 0.779, P = .028). The optimal LY30 cut point was determined based on these mortality data for each instrument. The TEG 6s showed superior mortality prediction than the TEG 5000 at lower LY30 levels (\u226510%), with likelihood ratios of 8.22 and 2.62 for the TEG 6s and TEG 5000, respectively. Patients with a TEG 6s CK LY30 of 10% or higher were significantly more likely to die, receive cryoprecipitate, receive transfusions, or receive massive transfusion than patients with a TEG 6s LY30 of 3.3% to 9.9% (all P &amp;lt; .01). Patients with a TEG 5000 LY30 of 17.1% or higher were significantly more likely to die or use cryoprecipitate (P &amp;lt; .05); transfusion and massive transfusion protocol were not significantly different. Whole blood spiking studies showed that 70 ng\/mL tissue plasminogen activator (tPA) achieved an average LY30 of approximately 10% for both instruments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>CK LY30 above the ULN is a sensitive but not specific cutoff for hyperfibrinolysis. At least moderately elevated CK LY30 carries more clinical portent on the TEG 6s instrument than on the TEG 5000. These TEG instruments are not sensitive to low concentrations of tPA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqad068","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T06:16:33Z","timestamp":1688710593000},"page":"455-465","source":"Crossref","is-referenced-by-count":5,"title":["Sensitivity and specificity of thromboelastography for hyperfibrinolysis: Comparison of TEG 5000 and TEG 6S CK LY30 systems"],"prefix":"10.1093","volume":"160","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8044-5314","authenticated-orcid":false,"given":"Christine","family":"Fuja","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Chicago , Chicago, IL , US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1509-2158","authenticated-orcid":false,"given":"Timothy C","family":"Carll","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago , Chicago, IL , US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Mikrut","sequence":"additional","affiliation":[{"name":"Clinical Laboratories, University of Chicago Medicine , Chicago, IL , US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey D","family":"Wool","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago , Chicago, IL , US"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"issue":"1","key":"2023110715001456000_CIT0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2014.09.003","article-title":"Fibrinolysis and the control of blood coagulation","volume":"29","author":"Chapin","year":"2015","journal-title":"Blood Rev."},{"issue":"8","key":"2023110715001456000_CIT0002","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1055\/s-0042-1756300","article-title":"Disseminated intravascular coagulation: the past, present, and future considerations","volume":"48","author":"Iba","year":"2022","journal-title":"Semin Thromb Hemost."},{"issue":"6","key":"2023110715001456000_CIT0003","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.bja.2022.08.033","article-title":"Tranexamic acid dose-response relationship for antifibrinolysis in postpartum haemorrhage during caesarean delivery: TRACES, a double-blind, placebo-controlled, multicentre, dose-ranging biomarker study","volume":"129","author":"Ducloy-Bouthors","year":"2022","journal-title":"Br J Anaesth."},{"issue":"2","key":"2023110715001456000_CIT0004","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1055\/s-0036-1598001","article-title":"Diagnosis and treatment of hyperfibrinolysis in trauma (a European perspective)","volume":"43","author":"Gall","year":"2017","journal-title":"Semin Thromb Hemost."},{"issue":"4","key":"2023110715001456000_CIT0005","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1055\/s-0033-1334144","article-title":"Clotting activation and hyperfibrinolysis in cirrhosis: implication for bleeding and thrombosis","volume":"39","author":"Violi","year":"2013","journal-title":"Semin Thromb Hemost."},{"issue":"4","key":"2023110715001456000_CIT0006","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/bja\/aew023","article-title":"Comparison between thrombelastography and thromboelastometry in hyperfibrinolysis detection during adult liver transplantation","volume":"116","author":"Abuelkasem","year":"2016","journal-title":"Br J Anaesth."},{"issue":"6","key":"2023110715001456000_CIT0007","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/TA.0000000000000341","article-title":"Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy","volume":"77","author":"Moore","year":"2014","journal-title":"J Trauma Acute Care Surg"},{"issue":"1","key":"2023110715001456000_CIT0008","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/TA.0000000000001699","article-title":"The hyperfibrinolytic phenotype is the most lethal and resource intense presentation of fibrinolysis in massive transfusion patients","volume":"84","author":"Taylor","year":"2018","journal-title":"J Trauma Acute Care Surg"},{"issue":"1","key":"2023110715001456000_CIT0009","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00068-017-0833-3","article-title":"Fibrinolysis in trauma: a review","volume":"44","author":"Madurska","year":"2018","journal-title":"Eur J Trauma Emerg Surg"},{"issue":"4","key":"2023110715001456000_CIT0010","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/medicines8040016","article-title":"Trauma-induced coagulopathy: overview of an emerging medical problem from pathophysiology to outcomes","volume":"8","author":"Savioli","year":"2021","journal-title":"Medicines (Basel)"},{"issue":"1","key":"2023110715001456000_CIT0011","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/TA.0000000000000885","article-title":"Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients","volume":"80","author":"Chapman","year":"2016","journal-title":"J Trauma Acute Care Surg"},{"issue":"1","key":"2023110715001456000_CIT0012","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41598-020-80010-z","article-title":"Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients","volume":"11","author":"Zuo","year":"2021","journal-title":"Sci Rep."},{"issue":"3","key":"2023110715001456000_CIT0013","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.thromres.2003.11.006","article-title":"Secretion of tissue plasminogen activator and plasminogen activator inhibitor 1 during cardiopulmonary bypass","volume":"112","author":"Chandler","year":"2003","journal-title":"Thromb Res."},{"issue":"2","key":"2023110715001456000_CIT0014","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/clpt.1989.120","article-title":"Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects","volume":"46","author":"Tanswell","year":"1989","journal-title":"Clin Pharmacol Ther."},{"issue":"5","key":"2023110715001456000_CIT0015","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/ijlh.12688","article-title":"Global assays of fibrinolysis","volume":"39","author":"Ilich","year":"2017","journal-title":"Int J Lab Hematol."},{"issue":"1S","key":"2023110715001456000_CIT0016","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/SHK.0000000000001686","article-title":"The role of TEG and ROTEM in damage control resuscitation","volume":"56","author":"Brill","year":"2021","journal-title":"Shock."},{"issue":"7","key":"2023110715001456000_CIT0017","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1177\/0003134821998684","article-title":"\u201cDeath diamond\u201d tracing on thromboelastography as a marker of poor survival after trauma","volume":"88","author":"Farrell","year":"2022","journal-title":"Am Surg."},{"issue":"6","key":"2023110715001456000_CIT0018","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/TA.0000000000000871","article-title":"The \u201cdeath diamond\u201d: rapid thrombelastography identifies lethal hyperfibrinolysis","volume":"79","author":"Chapman","year":"2015","journal-title":"J Trauma Acute Care Surg"},{"issue":"6","key":"2023110715001456000_CIT0019","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/TA.0b013e3182aa9c9f","article-title":"Fibrinolysis greater than 3% is the critical value for initiation of antifibrinolytic therapy","volume":"75","author":"Chapman","year":"2013","journal-title":"J Trauma Acute Care Surg"},{"issue":"3","key":"2023110715001456000_CIT0020","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/SLA.0b013e3181f09191","article-title":"Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma","volume":"252","author":"Kashuk","year":"2010","journal-title":"Ann Surg."},{"issue":"1","key":"2023110715001456000_CIT0021","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00068-014-0400-0","article-title":"Viscoelastic hemostatic fibrinogen assays detect fibrinolysis early","volume":"41","author":"Harr","year":"2015","journal-title":"Eur J Trauma Emerg Surg"},{"issue":"2","key":"2023110715001456000_CIT0022","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1213\/ANE.0b013e3181c92b23","article-title":"High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients","volume":"110","author":"Murkin","year":"2010","journal-title":"Anesth Analg."},{"key":"2023110715001456000_CIT0023","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jss.2017.04.028","article-title":"Tranexamic acid is associated with increased mortality in patients with physiological fibrinolysis","volume":"220","author":"Moore","year":"2017","journal-title":"J Surg Res."},{"issue":"suppl 6","key":"2023110715001456000_CIT0024","first-page":"S1","article-title":"Basic principles of viscoelastic testing","volume":"60","author":"Carll","year":"2020","journal-title":"Transfusion."},{"issue":"10","key":"2023110715001456000_CIT0025","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/ajh.26285","article-title":"Viscoelastic hemostatic assays: update on technology and clinical applications","volume":"96","author":"Faraoni","year":"2021","journal-title":"Am J Hematol."},{"issue":"3","key":"2023110715001456000_CIT0026","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3390\/jcm11030860","article-title":"Viscoelastic hemostatic assays: a primer on legacy and new generation devices","volume":"11","author":"Volod","year":"2022","journal-title":"J Clin Med"},{"issue":"6","key":"2023110715001456000_CIT0027","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1097\/SLA.0000000000002825","article-title":"Data-driven development of ROTEM and TEG algorithms for the management of trauma hemorrhage: a prospective observational multicenter study","volume":"270","author":"Baksaas-Aasen","year":"2019","journal-title":"Ann Surg."},{"issue":"5","key":"2023110715001456000_CIT0028","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ajcp\/aqab028","article-title":"Comparison of viscoelastic testing by rotational torsion and harmonic resonance methods","volume":"156","author":"Pham","year":"2021","journal-title":"Am J Clin Pathol."},{"issue":"2","key":"2023110715001456000_CIT0029","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/TA.0000000000002545","article-title":"A comparison between the TEG 6s and TEG 5000 analyzers to assess coagulation in trauma patients","volume":"88","author":"Neal","year":"2020","journal-title":"J Trauma Acute Care Surg"},{"issue":"1","key":"2023110715001456000_CIT0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12871-019-0717-7","article-title":"Assessment of agreement and interchangeability between the TEG5000 and TEG6S thromboelastography haemostasis analysers: a prospective validation study","volume":"19","author":"Lloyd-Donald","year":"2019","journal-title":"BMC Anesthesiol"},{"key":"2023110715001456000_CIT0031","author":"Clinical and Laboratory Standards Institute","year":"2010","edition":"3"},{"issue":"1","key":"2023110715001456000_CIT0032","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/clinchem\/46.1.38","article-title":"Measurement of different forms of tissue plasminogen activator in plasma","volume":"46","author":"Chandler","year":"2000","journal-title":"Clin Chem."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/160\/5\/455\/52783601\/aqad068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/160\/5\/455\/52783601\/aqad068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T19:09:22Z","timestamp":1699384162000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/160\/5\/455\/7220824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,7,7]]},"published-print":{"date-parts":[[2023,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqad068","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2023,7,7]]}}}